AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3370199
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (150 mg per day for 4 days)
Trial: 3370199
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (150 mg per day for 4 days) plus Gemeprost (1 mg on day 3)
Trial: 30798472
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide 500 mg
Trial: 30798472
Drug: Valproate sodium
RxNorm normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate sodium 400 mg
Trial: 31102145
Drug: Adjuvant bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant bevacizumab with oxaliplatin-based chemotherapy
Trial: 31102145
Drug: Standard oxaliplatin-based
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard oxaliplatin-based chemotherapy regimens
Trial: 28916436
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (solifenacin 5mg and mirabegron 25mg, increased to 50mg at week 4)
Trial: 26126306
Drug: Single-use negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use negative pressure wound therapy (NPWT) system
Trial: 21057704
Drug: MP-TF activity
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-TF activity before chemotherapy
Trial: 21057704
Drug: MP-TF activity
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-TF activity after chemotherapy
Trial: 17006119
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg intravenous lignocaine
Trial: 31016855
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment
Trial: 8804333
Drug: Episodic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Episodic infusion
Trial: 15319760
Drug: Spinal Manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Manipulation Treatment (SMT)
Trial: 6386484
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg etozolin (E)
Trial: 6386484
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg furosemide (F)
Trial: 29566437
Drug: Bimagrumab 10
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 10 mg/kg
Trial: 31397289
Drug: Bimagrumab 1
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 1 mg/kg
Trial: 31397289
Drug: Bimagrumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab (all doses)
Trial: 27052266
Drug: QFT-G positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QFT-G positive
Trial: 27052266
Drug: LTBI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTBI treatment acceptance
Trial: 17437728
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus thienopyridine
Trial: 16416663
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg IM one hr before surgery (Group A)
Trial: 16416663
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg into the surgical site (Group B)
Trial: 16416663
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg IM one hr before surgery plus 50 mg into the surgical site (Group C)
Trial: 9845561
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg twice daily for 1 week
Trial: 1579623
Drug: Flunitrazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (2 mg)
Trial: 2644129
Drug: High-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose Ara-C (3 g/m2 every 12 hours during 3 h of infusion)
Trial: 2644129
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of standard maintenance treatment after consolidation with 4 courses of DAT (Daunorubicin + Ara-C + 6-Thioguanine)
Trial: 2644129
Drug: High-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose Ara-C
Trial: 301745
Drug: Diflunisal (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (acute single dose)
Trial: 301745
Drug: Diflunisal (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (chronic multiple dose)
Trial: 301745
Drug: Diflunisal (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (high dosage open study)
Trial: 301745
Drug: Placebo (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (acute single dose)
Trial: 301745
Drug: Placebo (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chronic multiple dose)
Trial: 301745
Drug: Placebo (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (high dosage open study)
Trial: 29048511
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI, including local protocol implementation, education sessions, and feedback.
Trial: 29048511
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI.
Trial: 25728688
Drug: Internet-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based guided self-help intervention for PTSS, depression, and anxiety (10-week program based on cognitive behavior therapy)
Trial: 23742144
Drug: Multiparametric score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiparametric score based on clinical status, echo Doppler variables, NT-proBNP, eGFR, and drug therapies.
Trial: 21767341
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart twice‐daily
Trial: 21767341
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin detemir once‐daily (twice if required)
Trial: 15133775
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch, nicotine gum, or bupropion (33-50% of patients)
Trial: 8437976
Drug: Theophylline short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline short-term infusion (420 mg theophylline)
Trial: 8437976
Drug: Aminophylline short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminophylline short-term infusion (theophylline component 351.3 mg)
Trial: 8437976
Drug: Theophylline and
RxNorm normalized name: theophylline and adrenergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline and aminophylline infusions
Trial: 30854916
Drug: Ashwagandha extract
RxNorm normalized name: ashwagandha extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha extract (Shoden beads, 21 mg of withanolide glycosides per day)
Trial: 30110693
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice daily with tramadol hydrochloride 50 mg twice daily (as required)
Trial: 30110693
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 50 mg twice daily for 6 weeks
Trial: 24901856
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole, amoxicillin, and metronidazole)
Trial: 24901856
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole, tetracycline, metronidazole, and bismuth subcitrate)
Trial: 24901856
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both therapies combined)
Trial: 17984816
Drug: Hib‐MenC‐TT vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib‐MenC‐TT vaccine
Trial: 15691312
Drug: Second-line triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line triple therapy (7 days of omeprazole, amoxicillin and clarithromycin twice a day)
Trial: 15691312
Drug: Second-line quadruple
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line quadruple therapy (7 days of omeprazole twice a day, plus tetracycline, metronidazole and bismuth subcitrate three times a day)
Trial: 9706929
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids (lactated Ringer's solution 15 mL/kg within 15 min before spinal anesthesia)
Trial: 9706929
Drug: Intraoperative application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative application of both sedatives and opioids (subgroup)
Trial: 336818
Drug: S-carboxymethylcysteine (S-CMC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-carboxymethylcysteine (S-CMC; Mucodyne, Berk Pharmaceuticals)
Trial: 9643620
Drug: Intravenous bambuterol
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bambuterol
Trial: 9643620
Drug: Oral bambuterol
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bambuterol (single dose and repeated doses once daily for 7 days)
Trial: 9643620
Drug: Generated terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generated terbutaline from oral bambuterol
Trial: 9643620
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral dosing of bambuterol
Trial: 7945745
Drug: m-chlorophenylpiperazine (m-CPP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (m-CPP, 0.5 mg/kg p.o.)
Trial: 7945745
Drug: L-tryptophan (L-TRP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (L-TRP, 100 mg/kg i.v.)
Trial: 7945745
Drug: L-tryptophan (L-TRP)
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan (L-TRP)
Trial: 8194933
Drug: Routine Treatment
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Treatment
Trial: 3074860
Drug: Low-EE groups
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-EE groups (Education Only and Routine Treatment)
Trial: 3074860
Drug: Education Only
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education Only and Routine Treatment groups
Trial: 20581214
Drug: Oral celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral celecoxib from the evening before surgery until 48 hours after operation.
Trial: 20404219
Drug: Amlodipine-atenolol combination
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-atenolol combination
Trial: 8701624
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg clindamycin
Trial: 25025189
Drug: Hydrotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotherapy treatment (three individual sessions each week for four weeks)
Trial: 27220601
Drug: Rutin-containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutin-containing cream
Trial: 22658702
Drug: Methylphenidate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (1 mg/kg per day) for 90 days
Trial: 15377651
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine (10 mg)
Trial: 15377651
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine (10 mg) during hyperoxia
Trial: 10918923
Drug: Indinavir liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir liquid (80 mL, 10 mg/mL)
Trial: 10918923
Drug: Indinavir capsules
RxNorm normalized name: indinavir Oral Capsule
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir capsules (800 mg as two 400-mg capsules)
Trial: 10918923
Drug: Indinavir liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir liquid and capsules
Trial: 6600677
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg
Trial: 6303553
Drug: Misonidazole 1.200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole 1.200 mg/m2 orally on each treatment day
Trial: 27866658
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) with modulated electrohyperthermia (mEHT)
Trial: 22650145
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection using cervical Jiaji (EX‐B 2), Fengchi (GB 20), Ashi points, etc. with medications including simple Chinese herbs (Danggui injection, etc.), compound Chinese herbs (compound Danggui injection, etc.), simple western medicine (vitamin B family, etc.), and Chinese herbs combined with western medicine (compound Danggui injection combined with vitamin B12, etc.)
Trial: 20606481
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg orally thrice a day for 3 months
Trial: 18001211
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg purified isoflavones administered in 2 divided doses of 40 mg for 12 weeks
Trial: 11858482
Drug: s.c. melagatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. melagatran (1, 2 or 4 mg bid) for 2 days followed by oral ximelagatran (6, 12 or 24 mg bid) for 6-9 days
Trial: 11858482
Drug: dalteparin 5000
RxNorm normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dalteparin 5000 IU s.c. once daily for 8-11 days
Trial: 11858482
Drug: s.c. melagatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. melagatran plus oral ximelagatran
Trial: 7559370
Drug: Venlafaxine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (average dosage of approximately 350 mg/day during Weeks 2 to 4)
Trial: 28786523
Drug: Sevelamer 3200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer 3200 mg
Trial: 21959675
Drug: Tango dancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tango dancing program (twice weekly for 12 months)
Trial: 17324398
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks
Trial: 17324398
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 8 weeks
Trial: 17324398
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 12 weeks
Trial: 15466674
Drug: Comprehensive Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Cognitive Behavioral Therapy (CCBT)
Trial: 15466674
Drug: CCBT/Fluoxetine (CCBT/FLU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCBT/Fluoxetine (CCBT/FLU)
Trial: 15466674
Drug: Fluoxetine (FLU)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLU) and CCBT/FLU
Trial: 15466674
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CCBT/FLU)
Trial: 11799259
Drug: Interferon-alpha (IFN-a)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year
Trial: 11799259
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IFN-a treatment)
Trial: 2972597
Drug: Enoximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.5 mg/kg as a bolus)
Trial: 28628969
Drug: Remifentanil 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 100 μg/kg/min
Trial: 22712560
Drug: Ultrasound pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound pre-treatment (1 MHz, 1 W/cm²)
Trial: 22712560
Drug: Ultrasound simultaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound simultaneous treatment (1 MHz, 1 W/cm²)
Trial: 1727835
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (n = 166): Low-to-moderate-intensity endurance training, 40 minutes thrice weekly on a cycle ergometer, with training heart rate set at 70% of peak heart rate.
Trial: 1727835
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control group (n = 81): Attended weekly group talks.
Trial: 31498415
Drug: Topography-guided customized
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topography-guided customized ablation treatment (TCAT)
Trial: 22918828
Drug: FDM-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDM-guided treatment
Trial: 22918828
Drug: Conventional manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional manual therapy (MT)
Trial: 18578221
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence interventions
Trial: 8121459
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab bolus and infusion
Trial: 2763031
Drug: Dihydroergotamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine and heparin (DHE/Hep)
Trial: 27434512
Drug: Robot-assisted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted group activity with Paro, 30 minutes twice a week for 12 weeks
Trial: 15876467
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon alpha‐2b (1.5 microg/kg) and ribavirin (400‐800 mg)
Trial: 12828103
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (1g by continuous i.v. infusion starting 30 minutes before ERCP and continuing for 12 hours afterward)
Trial: 1579221
Drug: Aspartame (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (40 mg/kg)
Trial: 30064489
Drug: SODIS water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SODIS water treatment intervention
Trial: 18945637
Drug: Levosimendan 1
RxNorm normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 1 mg once or twice daily
Trial: 15716208
Drug: Control (non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-surgical treatment)
Trial: 12429622
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 followed by paclitaxel 200 mg/m2 (1- or 3-hour infusion) for six to seven cycles.
Trial: 12429622
Drug: Doxorubicin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose > 360 mg/m2
Trial: 12429622
Drug: Doxorubicin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose 420 mg/m2
Trial: 12429622
Drug: Doxorubicin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin dose < or = 360 mg/m2
Trial: 10430734
Drug: Low and
RxNorm normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low and high doses of budesonide with and without formoterol